The Electric Frontier in Cancer Treatment

“Electricity gives oncology two things at once: a way to read what a tumor is doing, and a way to act on it. The discipline is keeping those two honest about each other.”

— Erik A. Nilsen, PhD, Co-founder & Chief Technology Officer

As a clinician, I am wary of any framing that promises too much, so let me state the proposition carefully. There is growing research interest in treating electricity as both a diagnostic signal and a therapeutic tool in cancer. Both halves deserve scrutiny, and both are worth taking seriously.

The diagnostic half rests on a reproducible observation: cancer cells disturb the normal electrical order of tissue. They alter voltage gradients across membranes, change which ion channels are active, and weaken the gap junctions that let neighboring cells coordinate. These changes are not incidental — they are entangled with the behaviors that make cancer dangerous, including uncontrolled proliferation and the capacity to metastasize. If those electrical disturbances can be measured reliably, they may add information to the molecular and immunologic picture we already use.

Therapies under active study

On the therapeutic side, two approaches illustrate the range. Modulated electro-hyperthermia combines localized heating with field effects, and is discussed in terms of both thermal and nonthermal mechanisms. Tumor Treating Fields take a different route: low-intensity alternating electric fields, delivered through wearable arrays, that interfere with cell division. Tumor Treating Fields have been studied across several cancer types and are the most clinically advanced example of the category.

Researchers at work in an oncology laboratory. I find the most credible framing to be additive rather than substitutive. Bioelectric modulation is being investigated as a way to amplify therapies we already rely on — immunotherapy, chemotherapy, radiotherapy — rather than to stand in for them. That is a more modest claim than “a new cure,” and it is also a more testable one.

“Every tissue keeps an electrical rhythm. Understanding those rhythms is how the next generation of oncology research will think.”

— Nev Zubcevik, DO, Co-founder & Chief Medical Officer

Toward adaptive, measured treatment

What would make this clinically useful is adaptivity. Tumors are not static, and a fixed dose of anything tends to lose its grip as the target shifts. Electrome's work focuses on adaptive treatment frameworks that sense properties such as tumor impedance and respond with tailored stimulation, so the therapy tracks the disease instead of assuming it stands still.

That ambition depends on better measurement. Tracking a tumor's dynamic electrical state will require imaging, computational modeling, and AI-guided analytics working together — and it will require the same standard of evidence we demand of any oncology intervention. The promise is real; so is the obligation to prove it.

A cancer cell captured mid-division.